News Digest / Ticker: MIST

Ticker: MIST

07:01am, Tuesday, Aug 12, 2025

Milestone Pharma eyes Dec 13, 2025 PDUFA; $48.7M offering boosts runway amid debt, no revenue

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) - quick reality check Milestone is a clinical-stage cardio‑pharma company focused on etripamil (CARDAMYST). Management received a March 2025 CRL (CMC/manufacturing nitrosamine questions), submitted a response that the FDA accepted, and the agency set ...

08:06am, Wednesday, May 14, 2025

Milestone Pharmaceuticals Reports Q1 2025 Financial Losses Amid Etripamil Development Challenges

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) has presented its unaudited financial results for the three months ended March 31, 2025, highlighting several key developments and challenges facing the company. **Key Financial Highlights:** Revenue: No revenue reported for Q1 2025 or Q1 2024. Opera...